| 222.5 1.75 (0.79%) | 01-14 09:34 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 267.4  |
1-year : | 276.86 |
| Resists | First : | 228.94 |
Second : | 237.03 |
| Pivot price | 226.5 |
|||
| Supports | First : | 215.85 |
Second : | 179.58 |
| MAs | MA(5) : | 223.69 |
MA(20) : | 226.13 |
| MA(100) : | 224.11 |
MA(250) : | 204.65 |
|
| MACD | MACD : | -1.3 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 15.2 |
D(3) : | 25 |
| RSI | RSI(14): 43.6 |
|||
| 52-week | High : | 244.8 | Low : | 164.38 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ABBV ] has closed above bottom band by 17.2%. Bollinger Bands are 1.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 220.96 - 221.8 | 221.8 - 222.78 |
| Low: | 213.53 - 214.45 | 214.45 - 215.5 |
| Close: | 219.03 - 220.51 | 220.51 - 222.22 |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Tue, 13 Jan 2026
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know - Yahoo Finance
Mon, 12 Jan 2026
AbbVie secures tariff relief in drug pricing deal, pledges $100B investment (ABBV:NYSE) - Seeking Alpha
Mon, 12 Jan 2026
AbbVie to cut drug prices, pledges $100 billion for research - Reuters
Mon, 12 Jan 2026
Millions of Americans to see lower drug costs in new AbbVie–Trump pact - Stock Titan
Mon, 12 Jan 2026
AbbVie Down 3% in a Month: Why Holding the Stock Still Makes Sense - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 1,770 (M) |
| Shares Float | 1,760 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 75.2 (%) |
| Shares Short | 18,080 (K) |
| Shares Short P.Month | 18,720 (K) |
| EPS | 1.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.5 |
| Profit Margin | 4 % |
| Operating Margin | 35.5 % |
| Return on Assets (ttm) | 9.5 % |
| Return on Equity (ttm) | 137.9 % |
| Qtrly Rev. Growth | 9.1 % |
| Gross Profit (p.s.) | 24.07 |
| Sales Per Share | 33.69 |
| EBITDA (p.s.) | 16.67 |
| Qtrly Earnings Growth | -88.7 % |
| Operating Cash Flow | 20,860 (M) |
| Levered Free Cash Flow | 20,800 (M) |
| PE Ratio | 165.97 |
| PEG Ratio | 0 |
| Price to Book value | -147.17 |
| Price to Sales | 6.55 |
| Price to Cash Flow | 18.73 |
| Dividend | 1.63 |
| Forward Dividend | 0 |
| Dividend Yield | 0.7% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|